The aim of this study was to investigate the factors predicting clinical pregnancy rate of in vitro fertilization-embryo transfer (IVF-ET).
Introduction
Synchronized mature high-quality follicles as well as normally fertilized and developed embryos were essential for in vitro fertilization-embryo transfer (IVF-ET). Human chorionic gonadotrophin (HCG) plays an unique role in promoting final oocyte maturation and inducing ovulation, so it is important for accurate and proper application of HCG in IVF-ET. Some studies have indicated that the serum HCG level after HCG injection or HCG injection dose is related to clinical pregnancy rate, number of retrieved oocytes and metaphase II (MII) rate, but there has been considerable debate about it. [1] [2] [3] [4] [5] Therefore, in this study, the data from the patients who underwent HCG subcutaneous injection according to the luteal phase standard long-term program were retrospectively analyzed to explore the clinical pregnancy rate-related factors including serum HCG levels at 12 and 36 hours after HCG trigger as well as the serum HCG ratio at 36 hours to 12 hours (36 h/12 h). Different from previous studies, we observed the effect of serum HCG ratio (36 h/12 h) on the clinical pregnancy rate for the first time, providing a new guidance for clinical practice.
Materials and methods
All study methods were approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. All the subjects enrolled into the study gave written informed consent to participate.
Subjects
A total of 9960 patients who received artificial assisted reproductive technology in our Reproductive Medicine Center from January 2009 to December 2017 and were in line with the Editor: N/A. YLZ and FZW equally contributed to this study.
following inclusion and exclusion criteria, were enrolled in this study. In the 9960 patients, 7242 underwent IVF-ET, 2635 intracytoplasmic sperm injection (ICSI) and 83 IVF+ICSI (rescue ICSI).
Inclusion criteria were (1) patients receiving fresh cycle;
(2) ovulation induction performed using the standard long-term luteal phase regimen; (3) available embryo transfer; (4) patients receiving subcutaneous injection of 250 mg HCG (Aize, Merck Serono SPA, Geneva, Switzerland); (5) serum b-HCG and E2 levels were detected at 12 hours and 36 hours after HCG trigger; (6) the first cycle of assisted pregnancy; and (7) the sterility caused by fallopian tube factors and male factor.
Exclusion criteria were
(1) patients with polycystic ovary syndrome (PCOS) which was diagnosed according to Rotterdam criteria; [6] (2) patients with low response which was diagnosed according to Bologna criteria [7] and (3) patients with high ovarian response which was diagnosed according to the reference. [8] 
Controlled ovarian hyper-stimulation protocol
Subcutaneous injection of short-acting gonadotropin-releasing hormone agonist (0.05-0.1 mg of of Diphereline, Ipsen, Paris, France) was performed once a day in the mid-luteal phase of the previous cycle. After complete pituitary down regulation, gonadotrophin (Gn), a high-purity recombinant follicle stimulating hormone (r-FSH, Merck Serono SPA, Geneva, Switzerland, or HMG, Le Baode, Shanghai Lizhu Pharmaceutical Co. Ltd., Shanghai, China), was used until HCG day. Gn dose was adjusted according to patients' specific conditions. Oocyte retrieval, insemination, embryo transfer and corpus luteum support were performed according to our routine protocols. [9, 10] 
Diagnosis of pregnancy
After 14 and 18 days of embryo transfer, b-hCG>50 mIU/ml was regarded as biochemical pregnancy. Thirty-five days after embryo transfer, ultrasound showing a gestational sac was regarded as clinical pregnancy.
Determination of HCG and E2 levels
Venous blood (2 to 3 ml) was collected at 12 hours and 36 hours after HCG trigger. The blood was centrifuged at 2000 r/min for 15 minutes. The supernatant was taken and tested using German Roche Automated Chemiluminescence Kits to determine HCG and E2 levels. The intra-assay coefficient of variation was <5% and the inter-assay coefficient of variation was <7%.
Data analysis
Statistical treatment was performed using SPSS21.0 software. The general data of patients were expressed as mean ± standard deviation (x ± s) and clinical pregnancy rate was expressed as percentage (%). The comparison between two groups was performed using t test. Variance Analysis was used for the comparison among multiple groups. Rate comparison was carried out using chi-square test. The statistical significance was established at P < .05. The correlations of clinical pregnancy rate with pregnancy rate-related factors were analyzed using logistic regression analysis. The OR value and receiver operating characteristic (ROC) curve of the clinical pregnancy rate and a 95% confidence interval were calculated.
Results

General data in the 9960 patients
General data of the 9960 cycles in line with the inclusion criteria and the exclusion criteria in this study are shown in Table 1 . The patients were 30.97 ± 5.16 (range 20-50) years old and the duration of infertile were 4.62 ± 3.49 years (range 0-23) ( Table 1 ). The total clinical pregnancy rate was 51.33%. According to the serum HCG level after HCG trigger, all patients were divided into 4 groups including <50 mIU/ml, ≥50 and <100 mIU/ml, ≥100 and <200 mIU/ml, and ≥200 mIU/ml groups. According to the serum HCG ratio (36 h/12 h) after HCG trigger, all patients were divided into 3 groups including <0.88, 0.88-1.06 and >1.06 groups ( Table 1 ). According to different assisted pregnancy modes, all patients were divided into 3 groups including IVF, ICSI, and IVF/ICSI groups.
Comparison of general data between the clinical pregnant group and non-pregnant group
As shown in Table 2 , there were significant differences between clinical pregnancy group and non-pregnancy group in age, BMI, duration of infertility, number of retrieved oocytes and Gn days (all P = .000), suggesting that age, BMI, duration of infertility, number of retrieved oocytes and Gn days are related to the clinical pregnancy rate.
Comparison of the clinical pregnancy rate between different HCG level groups
There were no significant differences in the clinical pregnancy rate among the <50 mIU/ml, ≥50 and <100 mIU/ml, ≥100 and <200 mIU/ml, and ≥200 mIU/ml groups at both 12 hours and 36 hours after HCG trigger (all P >.05, Table 3 ). However, there were significant differences in the clinical pregnancy rate among <0.88, 0.88-1.06 and >1.06 groups (P = .002). Further comparison of 2 groups indicated that the clinical pregnancy rate was significantly higher in the >1.06 group than in the <0.88 (P = .001) and 0.88-1.06 groups (P = .011), but there was no significant difference in the clinical pregnancy rate between the <0.88 group and 0.88-1.06 group (P = .793). Also, there were significant differences in the clinical prgnancy rate among IVF, ICSI, and IVF/ICSI groups (P = .001). Further comparison of 2 groups indicated that the clinical pregnancy rate was significantly higher in the ICSI group than in the IVF group (P = .000), but there were no significant differences in the clinical pregnancy rate between ICSI group and IVF/ICSI group (P = .106) as well as between the IVF group and IVF/ICSI group (P = .419) ( Table 4 ). The area under ROC curve was 0.598, sensitivity was 0.631 and specificity was 0.218 ( Fig. 1) . 
Discussion
Accurate and appropriate application of HCG in IVF-ET is essential for obtaining good pregnancy outcome. At present, it has reported that the serum HCG level after HCG trigger is related to the number of retrieved oocytes, MII rate, BMI and pregnancy rate. [11] [12] [13] However, there are some opposite opinions. [3, 5] This may be due to different sample sizes, patients' specific conditions and ovarian hyper-stimulation protocols. Therefore, we carried out the large-sample study in which the patients with low response and high response were excluded and all patients received the luteal phase standard long-term program in order to find relatively accurate conclusion for this issue. The results of this study indicated that the serum HCG level at 12 hours and 36 hours after HCG trigger all failed to influence the clinical pregnancy rate, but the serum HCG ratio (36 h/12 h) >1.06 was signifiacntly correlated with the clinical pregnancy rate as compared with the HCG ratio (36 h/12 h) of 0.88-1.06 or <0.88. Logistic regression analysis suggested that the serum HCG ratio >1.06 is a predictive factor for the clinical pregnancy rate. When the serum HCG ratio (36 h/12 h) was more than 1.06, the clinical pregnancy rate was significantly increased, the number of retrieved oocytes was also significantly increased, but the serum E2 level at 36 hours after HCG trigger was significantly The comparison of the clinical pregnancy rate between different groups (n, %). [14] compared HCG half-life and time of serum HCG concentration peak after use of 5000 IU of HCG between intramuscular injection and subcutaneous injection, and found that compared with intramuscular injection, the peak of serum HCG concentration was significantly delayed (P = .01) and the serum half-life was significantly prolonged (P = .01) in subcutaneous injection. Shah et al [15] also reported that the serum HCG concentration peak, area under the curve (AUC) and average HCG concentration were significantly higher in the intramuscular injection than in the subcutaneous injection. Therefore, the serum HCG concentration at the same time point after HCG trigger varies according to different ways of administration. In most previous studies, the effect of HCG concentration only at 12 hours or 36 hours on pregnancy outcome was observed. In order to thoroughly and dynamically observe the effects of HCG concentration on the clinical pregnancy rate, we observed the effects of HCG concentrations both at 12 hours and at 36 hours after HCG trigger as well as HCG ratio (36 h/12 h) on the clinical pregnancy rate in this study.
Groups
Stefanis et al [16] retrospectively analyzed the correlations of HCG levels at 12 hours and 36 hours after 5000 IU HCG subcutaneous injection with BMI, number of retrieved oocytes and pregnancy outcome in 149 IVF-assisted patients and found that there were no correlations of HCG levels with BMI, number of retrieved oocytes, fertilization rate and biochemical pregnancy rate. A prospective study indicated that there were no correlations of the serum HCG level at 36 hours after recombinant HCG injection with number of retrieved oocytes and clinical pregnancy rate, but there were negative correlations of the serum HCG level with BMI and age. [3] Zhou et al [1] believe that the blood HCG level at 12 hours after HCG injection may be used as a predictive value for IVF/ICSI clinical outcome, namely that when blood HCG level is more than 201.2 mIU/ml, the clinical pregnancy rate significantly improved with a sensitivity of 74.6% and a specificity of 61.7%.
To date, there is still considerable debate about whether the serum HCG level after HCG injection can predict IVF/ICSI pregnancy outcome. In order to further clarify this issue, this study retrospectively analyzed 9960 IVF/ICSI cycles. The results of this study indicated that the serum HCG levels at 12 hours and 36 hours after HCG injection all failed to influence the clinical pregnancy rate, but the serum HCG ratio (36 h/12 h) >1.06 was significantly correlated the clinical pregnancy rate and the number of retrieved oocytes as compared with the HCG ratio (36 h/12 h) of 0.88-1.06 or <0.88, demonstrating that the serum HCG ratio (36 h/12 h) is related to the clinical pregnancy rate and the number of retrieved oocytes.
Embryo quality and endometrial receptivity are the key factors associated with pregnancy outcomes. One of HCG important roles is to regulate endometrial receptivity. [17, 18] Schumacher et al [19] have found that HCG can attract immune T lymphocytes which regulate maternal and infant immune tolerance. In addition, current studies suggested that controlled ovulationinduced serum E2 level may affect endometrial receptivity. [20] [21] [22] [23] Valbuena et al [24] have reported that high E2 level (range 10 -8 M It has been demonstrated that the super-physiological dose of serum E2 can decrease the endometrial receptivity, although the relevant mechanism is not clear. [25, 26] In this study, the E2 level was significantly lower in the HCG ratio (36 h/12 h)>1.06 group than in the HCG ratios (36 h/12 h) of 0.88-1.06 and <0.88 groups, which may be conducive to pregnancy. In summary, the HCG levels at 12 hours and 36 hours after HCG trigger are not related to the clinical pregnancy rate, but the HCG ratio (36 h/12 h) is related to the clinical pregnancy rate because when the serum HCG ratio (36 h/12 h) was >1.06, the clinical pregnancy rate significantly increased as compared with the serum HCG ratios of <0.88 and 0.88-1.06. Low E2 level in the serum HCG ratio (36 h/12 h) >1.06 group may be conducive to pregnancy. The serum HCG ratio of 1.06 was significantly correlated with the clinical pregnancy rate, so it may be used as a predictor of IVF-ET clinical pregnancy rate. 
